2-[6-(4-amino-5-oxo-7,8-dihydro-6H-oxepino[2,3-d]pyrimidin-6-yl)-2-methyl-1-oxo-3,4-dihydronaphthalen-2-yl]acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-[6-(4-amino-5-oxo-7,8-dihydro-6H-oxepino[2,3-d]pyrimidin-6-yl)-2-methyl-1-oxo-3,4-dihydronaphthalen-2-yl]acetic acid
• 化学式: C₂₁H₂₁N₃O₅
• 分子量: 395.4
• InChiKey: IBYOCRZEACGMPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  133
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20140378434A1

  公开（公告）日：2014-12-25

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  本发明涉及一种新型化合物，其为酰基辅酶A: 二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，含有它们的制药组合物，制备它们的过程以及它们在预防或治疗与DGAT-1功能障碍相关的疾病或调节DGAT-1活性可能具有治疗益处的治疗中的使用，包括但不限于肥胖症，肥胖相关疾病，高三酰甘油血症，高脂蛋白血症，乳糜微粒血症，脂质代谢异常，非酒精性脂肪性肝炎，糖尿病，胰岛素抵抗，代谢综合症，丙型肝炎病毒感染以及痤疮或其他皮肤疾病。
• Novel Compounds as Diacylglycerol Acyltransferase Inhibitors
  申请人：Qin Donghui

  公开号：US20140080809A1

  公开（公告）日：2014-03-20

  This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.

  本发明涉及一种新型化合物，它们是酰基辅酶A：二酰基甘油酰基转移酶1（DGAT-1）的抑制剂，以及包含它们的制药组合物、它们的制备过程，以及它们在预防或治疗与DGAT-1功能障碍相关的疾病或调节DGAT-1活性可能具有治疗益处的疾病中的使用，包括但不限于肥胖症，肥胖相关疾病，高甘油三酯血症，高脂蛋白血症，乳糜微粒血症，脂质代谢异常，非酒精性脂肪肝，糖尿病，胰岛素抵抗，代谢综合征，丙型肝炎病毒感染以及痤疮或其他皮肤疾病。
• US8859536B2
  申请人：——

  公开号：US8859536B2

  公开（公告）日：2014-10-14
• US9040517B2
  申请人：——

  公开号：US9040517B2

  公开（公告）日：2015-05-26
• US9273069B2
  申请人：——

  公开号：US9273069B2

  公开（公告）日：2016-03-01